RP463: A stabilized technetium-99m complex of a hydrazino nicotinamide derivatized chemotactic peptide for infection imaging

A HYNIC-conjugated chemotactic peptide (fMLFK-HYNIC) was labeled with Tc-99m using tricine and TPPTS as coligands. The combination of fMLFK-HYNIC, tricine, and TPPTS with Tc-99m produced a ternary ligand complex [Tc-99m(fMLFK-HYNIC)(tricine)(TPPTS)] (RP463). RP463 was synthesized either in two steps, in which the binary Ligand complex [Tc-99m(fMLFK-HYNIC)(tricine)(2)] (RP469) was formed first and then reacted with TPPTS, or in one step by direct reduction of [Tc-99m]pertechnetate with stannous chloride in the presence of fMLFK-HYNIC, tricine, and TPPTS. The radiolabeling yield for RP463 was usually greater than or equal to 90% using 10 mu g of fMLFK-HYNIC an 100 mCi of [Tc-99m]pertechnetate. Unlike RP469, which decomposed rapidly in the absence of excess tricine coligand, RP463 was stable in solution for at least 6 h. [Tc-99]RP463 was prepared and characterized by HPLC and electrospray mass spectrometry. In an in vitro assay, [Tc-99]RP463 showed an IC50 Of 2 nM against binding of [H-3]fMLF to receptors on PMNs. [Tc-99]RP463 also induces effectively the superoxide release of polymorphonuclear leukocytes (PMNs) with an EC50 value of 0.2 +/- 0.2 nM. The localization of RP463 in the infection foci was assessed in a rabbit infection model. RP463 was cleared from the blood faster than RP469 and was excreted mainly through the renal system. As a result of rapid blood clearance and increased uptake, the target-to-background ratios continuously increased from 1.5 +/- 0.2 at 15 min postinjection to 7.5 +/- 0.4 at 4 h postinjection. Visualization of the infected area could be as early as 2 h. A transient decrease in white blood cell count of 35% was observed during the first 30 min after injection of the HPLC-purified RP463 in the infected rabbit. This suggests that future research in this area should focus on developing highly potent antagonists for chemotactic peptide receptor or other receptors on PMNs and monocytes.